Guobang Pharma Ltd
Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives.… Read more
Guobang Pharma Ltd (605507) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.038x
Based on the latest financial reports, Guobang Pharma Ltd (605507) has a cash flow conversion efficiency ratio of 0.038x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥311.27 Million) by net assets (CN¥8.28 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Guobang Pharma Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Guobang Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Guobang Pharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guobang Pharma Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Security & Fire Co Ltd Class A
SHG:600654
|
-0.009x |
|
Hanwha Corp Preferred
KO:00088K
|
0.032x |
|
Great Wall Enterprise Co Ltd
TW:1210
|
0.061x |
|
Nippon Light Metal Holdings Company Ltd
F:N9L
|
N/A |
|
Hanwha Life
KO:088350
|
0.068x |
|
Zibo Qixiang Tengda Chemical Co Ltd
SHE:002408
|
0.009x |
|
Bank Handlowy w Warszawie SA
WAR:BHW
|
-0.153x |
|
Fortrea Holdings Inc.
NASDAQ:FTRE
|
0.149x |
Annual Cash Flow Conversion Efficiency for Guobang Pharma Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Guobang Pharma Ltd from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥8.05 Billion | CN¥706.41 Million | 0.088x | +26.26% |
| 2023-12-31 | CN¥7.44 Billion | CN¥516.76 Million | 0.069x | -51.12% |
| 2022-12-31 | CN¥7.15 Billion | CN¥1.02 Billion | 0.142x | +611.99% |
| 2021-12-31 | CN¥6.35 Billion | CN¥-176.18 Million | -0.028x | -111.84% |
| 2020-12-31 | CN¥3.27 Billion | CN¥767.70 Million | 0.234x | +39.13% |
| 2019-12-31 | CN¥2.62 Billion | CN¥440.86 Million | 0.169x | -19.35% |
| 2018-12-31 | CN¥2.59 Billion | CN¥541.68 Million | 0.209x | +211.60% |
| 2017-12-31 | CN¥2.21 Billion | CN¥148.03 Million | 0.067x | -- |